Meropenem pharmacokinetics in patients on continuous hemodiafiltration

DOI Web Site
  • Mochida Yasuhiro
    Department of Nephrology, Immunology, and Vascular Medicine, Shonan Kamakura General Hospital
  • Yasu Takeo
    Department of Pharmacology, Shonan Kamakura General Hospital
  • Matsumoto Kana
    Doshisha Women’s College of Liberal Arts, Faculty of Pharmacentical Sciences, Department of Clinical Pharmucy
  • Morita Kunihiko
    Doshisha Women’s College of Liberal Arts, Faculty of Pharmacentical Sciences, Department of Clinical Pharmucy
  • Iwagami Masao
    Department of Nephrology, Immunology, and Vascular Medicine, Shonan Kamakura General Hospital
  • Furuya Rei
    Department of Nephrology, Immunology, and Vascular Medicine, Shonan Kamakura General Hospital
  • Tsutsumi Daimu
    Department of Nephrology, Immunology, and Vascular Medicine, Shonan Kamakura General Hospital
  • Ishioka Kunihiro
    Department of Nephrology, Immunology, and Vascular Medicine, Shonan Kamakura General Hospital
  • Maesato Kyoko
    Department of Nephrology, Immunology, and Vascular Medicine, Shonan Kamakura General Hospital
  • Oka Machiko
    Department of Nephrology, Immunology, and Vascular Medicine, Shonan Kamakura General Hospital
  • Moriya Hidekazu
    Department of Nephrology, Immunology, and Vascular Medicine, Shonan Kamakura General Hospital
  • Hidaka Sumi
    Department of Nephrology, Immunology, and Vascular Medicine, Shonan Kamakura General Hospital
  • Otake Takayasu
    Department of Nephrology, Immunology, and Vascular Medicine, Shonan Kamakura General Hospital
  • Kobayashi Shuzo
    Department of Nephrology, Immunology, and Vascular Medicine, Shonan Kamakura General Hospital

Bibliographic Information

Other Title
  • 持続的血液濾過透析（CHDF）施行患者におけるメロペネム（MEPM）の薬物動態
  • ジゾクテキ ケツエキ ロカ トウセキ(CHDF)シコウ カンジャ ニ オケル メロペネム(MEPM)ノ ヤクブツ ドウタイ

Search this article

Description

<p>Pharmacokinetics of meropenem (MEPM) in patients undergoing continuous hemodiafiltrarion (CHDF) has not been fully elucidated in Japan. Therefore, we evaluated the pharmacokinetics of MEPM to obtain optimal dose and times of MEPM infusion under CHDF therapy. Eight patients with multiple organ failure and anuria due to sepsis who needed CHDF treatment were injected 0.5 gram of MEPM twice daily. Among 8 patients, 4 patients used polysulfone (PS) membrane and 4 patients used polymethyl methacrylate (PMMA) membrane, and blood concentrations of MEPM were sequentially evaluated. Time above MIC (%T＞MIC) of MEPM more than 40～50% is usually thought to be effective and sufficient to sterilize bacteria. In our study, drip infusion of MEPM 0.5 gram twice daily under CHDF(blood flow 100mL/minute, dialysate flow 300mL/hour, replacement flow 300 mL/hour)could achieve effective therapeutic dose (%T＞MIC more than 50%) if the MIC of bacteria against MEPM was below 4µg/mL. Blood concentration of MEPM did not differ between PS and PMMA group. In critically ill patients with severe infection, adequate administration of antibiotics is crucial. Therefore, evidence of antibiotic pharmacokinetics under CHDF therapy should be accumulated to obtain optimal effect for such patients. </p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top